Clinical trial · Observational
Whole Body MRI in Oncology
NCT06895291CI-TRIAL-00087851ONCO-MRIrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Advanced Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Monoclonal Gammopathy of Undetermined Significance | Monoclonal Gammopathy of Undetermined Significance | ONTOLOGY_EXACT | 0.98 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Smoldering Multiple Myeloma | Smoldering Multiple Myeloma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole Body-Magnetic Resonance Imaging (WB-MRI) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Patients affected by Monoclonal plasma cell disorders
- description
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM).
- interventionNames
- Diagnostic Test: Whole Body-Magnetic Resonance Imaging (WB-MRI)
- label
- Patients affected by advanced prostate cancer (APC) or advanced breast cancer (ABC)
- description
- Patients affected by advanced prostate (APC) or breast cancer (ABC) with high suspicious of metastasis particularly in case of diagnostic doubt in other imaging methods (Computed tomography (CT), Positron Emission Computed Tomography (PET/CT), Bone Scintigraphy (BS)).
- interventionNames
- Diagnostic Test: Whole Body-Magnetic Resonance Imaging (WB-MRI)
- label
- Patients affected by Lymphomas.
- description
- Patients affected by Lymphomas.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above. * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged ≥ 18 years. * Life expectancy greater than 3 months. Exclusion Criteria: * Patients with MRI-unsafe prostheses and devices. * Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete.
References
Publications (0)
Data not yet available
No reference posted for this study.